#biotech-partners

#biotech-partners

You just have to immerse yourself in it. You should just constantly be building. That's what's going to give you the best chance of having the relevant skill set that is needed to make a difference in technology.

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Small organic molecules underpin modern life, from medicines and flavours to advanced materials. Much of this functional diversity comes from shape: modest changes in a molecule's 3D structure can completely change its properties.

Nicolas Sauvage, president of TDK Ventures, will explain the unique operations of corporate VCs and what founders should know about attracting investment.

The Stanley Family Foundation announced another $280 million for the Stanley Center for Psychiatric Research at Broad Institute earlier this month, bringing its total contributions to the Massachusetts-based nonprofit over $1 billion.

Modern scientific societies are increasingly vulnerable due to their dependence on membership fees and journal subscriptions, which are being challenged by the rise of virtual networking and open-access publishing.

Over two-thirds said they recommend their students consider careers outside academia. The majority had delayed hiring in their labs, and one-third had laid off workers. More than one in six said they have lost researchers to institutions in other countries since Trump took office. Sixty-eight percent said funding cuts and federal policy changes had moderately or significantly reduced the scope of their work.

But he'd been considering an idea for new technology-an autonomous, wind-powered cargo ship. Then, while on paternity leave in 2024, he discovered a free program that helps scientists and engineers launch businesses for the first time. Weeks after finishing the program, called 5050, Cymbalist had launched a startup called Clippership. The company's first ship is being built in the Netherlands this year. Without the accelerator, he says, the company likely wouldn't exist.

Biology is undergoing a transformation. After centuries of studying life as it evolves naturally, researchers are now using a combination of computation and genome engineering to intervene, generating new proteins and even whole bacteria from scratch. The use of artificial-intelligence tools to design biological components, an approach known as generative biology, is set to turbocharge this area of research. Just last year, scientists used AI-assisted design to produce artificial genes that can be expressed in mammalian cells.

Martschenko's argument is largely that genetic research and data have almost always been used thus far as a justification to further entrench extant social inequalities. But we know the solutions to many of the injustices in our world-trying to lift people out of poverty, for example-and we certainly don't need more genetic research to implement them. Trejo's point is largely that more information is generally better than less.

We provide thought partnership. When a company is developing a drug, there's a lot of work involved, such as understanding the science, designing a study and generating good data. We come in and explain what the standard of care looks like today for their patient population, and what we think it will look like in five to eight years or whenever they plan to launch their therapy.